On September 30, 2025, Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) announced its financial results for the quarter ended June 30, 2025, and for the full fiscal year 2025. The company reported a net loss of $2.14 million for the quarter and a net loss of $8.48 million for the year. Cash and cash equivalents stood at $11.63 million at the end of the reporting period.
Operating expenses for the quarter totaled $2.33 million, comprising $1.13 million in research and development and $1.20 million in general and administrative costs. Other income and expenses included $17,439 of interest expense, $122,583 of interest income, $81,343 of grant income, and $431 of other items, resulting in a net loss of $2.14 million. The weighted average shares outstanding were 41.08 million, yielding a net loss per share of $0.05.
For the full year, operating expenses were $9.22 million, with $4.30 million in R&D and $4.92 million in G&A. The company’s cash position of $11.63 million, combined with a $3.0 million loan facility, provides a runway of at least 12 months from the filing date. Anebulo also announced a proposed reverse stock split to keep the number of record holders below 300, a strategic move to maintain its Nasdaq listing.
The company continues to advance its intravenous formulation of selonabant for pediatric cannabis toxicity, with ongoing clinical studies and regulatory engagement. No new product launches or regulatory approvals were reported in this release.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.